Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome by Grosse, Claudia et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Oncogenic driver mutations in Swiss never smoker patients with lung
adenocarcinoma and correlation with clinicopathologic characteristics and
outcome
Grosse, Claudia ; Soltermann, Alex ; Rechsteiner, Markus ; Grosse, Alexandra
Abstract: PURPOSE Lung cancer in never smokers is recognized as a distinct molecular, clinicopatho-
logic and epidemiologic entity. The aim of the study was to investigate the molecular profile in Swiss
never smokers with lung adenocarcinoma and to correlate the mutation status with clinicopathologic and
demographic patient characteristics and outcome. METHODS One hundred thirty-eight never smokers
diagnosed with lung adenocarcinoma at the University Hospital Zurich between 2011-2018 were included
in the study. Data from the electronic medical records were reviewed to characterize clinicopathologic
and demographic features, molecular profile, treatment and outcome. RESULTS The majority of patients
were female (58.7%) with a median age at diagnosis of 64.5 years (range, 27.1-94.2 years). The most
common mutations were EGFR (58.7%) followed by ALK (12.3%), TP53 (5.8%), MET (5.8%), KRAS
(4.3%), ERBB2 (4.3%), PIK3CA (2.9%), BRAF (2.2%), ROS1 (1.4%), RET (1.4%), CTNNB1 (0.7%),
PARP1 (0.7%), TET1 (0.7%) and PIK3CG (0.7%). Median overall survival (mOS) was 51.0 months
(mo). Early clinical stage (p = 0.002) and treatment with targeted therapy (HR 2.53, 95% CI 1.35-4.74,
p = 0.004) were independently associated with longer mOS. Patients with oncogenic driver mutations
had significantly longer mOS (52.2 mo) compared to patients without mutations (16.9 mo) (HR 3.38,
95% CI 1.52-7.55, p = 0.003). Besides, patients with EGFR mutated (57.8 mo) or ALK rearranged (59.9
mo) tumors had significantly longer mOS compared to the EGFR wildtype (35.0 mo), ALK wildtype
(46.5 mo) and pan-negative (16.9 mo) cohorts (HR 2.35, 95% CI 1.37-4.04, p = 0.002; HR 7.80, 95% CI
3.28-18.55, p < 0.001; HR 3.96, 95% CI 1.21-12.95, p = 0.023 and HR 34.78, 95% CI 3.48-34.65, p =
0.003). CONCLUSION Never smokers with lung adenocarcinoma display distinct clinicopathologic and
molecular features and are characterized by a high incidence of targetable mutations. Never smokers
with targetable mutations have significantly longer survival compared to patients without mutations.
DOI: https://doi.org/10.1371/journal.pone.0220691
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-178849
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Grosse, Claudia; Soltermann, Alex; Rechsteiner, Markus; Grosse, Alexandra (2019). Oncogenic driver
mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic
characteristics and outcome. PLoS ONE, 14(8):e0220691.
DOI: https://doi.org/10.1371/journal.pone.0220691
2
RESEARCH ARTICLE
Oncogenic driver mutations in Swiss never
smoker patients with lung adenocarcinoma
and correlation with clinicopathologic
characteristics and outcome
Claudia GrosseID1*, Alex Soltermann1, Markus Rechsteiner2, Alexandra Grosse1
1 Institute of Pathology and Molecular Pathology, Clinical Pathology, University Hospital Zurich, Zurich,
Switzerland, 2 Institute of Pathology and Molecular Pathology, Diagnostic Molecular Pathology, University
Hospital Zurich, Zurich, Switzerland
* claudiagrosse@gmx.at
Abstract
Purpose
Lung cancer in never smokers is recognized as a distinct molecular, clinicopathologic and
epidemiologic entity. The aim of the study was to investigate the molecular profile in Swiss
never smokers with lung adenocarcinoma and to correlate the mutation status with clinico-
pathologic and demographic patient characteristics and outcome.
Methods
One hundred thirty-eight never smokers diagnosed with lung adenocarcinoma at the Univer-
sity Hospital Zurich between 2011–2018 were included in the study. Data from the electronic
medical records were reviewed to characterize clinicopathologic and demographic features,
molecular profile, treatment and outcome.
Results
The majority of patients were female (58.7%) with a median age at diagnosis of 64.5 years
(range, 27.1–94.2 years). The most common mutations were EGFR (58.7%) followed by
ALK (12.3%), TP53 (5.8%), MET (5.8%), KRAS (4.3%), ERBB2 (4.3%), PIK3CA (2.9%),
BRAF (2.2%), ROS1 (1.4%), RET (1.4%), CTNNB1 (0.7%), PARP1 (0.7%), TET1 (0.7%)
and PIK3CG (0.7%). Median overall survival (mOS) was 51.0 months (mo). Early clinical
stage (p = 0.002) and treatment with targeted therapy (HR 2.53, 95% CI 1.35–4.74, p =
0.004) were independently associated with longer mOS. Patients with oncogenic driver
mutations had significantly longer mOS (52.2 mo) compared to patients without mutations
(16.9 mo) (HR 3.38, 95% CI 1.52–7.55, p = 0.003). Besides, patients with EGFR mutated
(57.8 mo) or ALK rearranged (59.9 mo) tumors had significantly longer mOS compared to
the EGFR wildtype (35.0 mo), ALK wildtype (46.5 mo) and pan-negative (16.9 mo) cohorts
(HR 2.35, 95% CI 1.37–4.04, p = 0.002; HR 7.80, 95% CI 3.28–18.55, p < 0.001; HR 3.96,
95% CI 1.21–12.95, p = 0.023 and HR 34.78, 95% CI 3.48–34.65, p = 0.003).
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Conclusion
Never smokers with lung adenocarcinoma display distinct clinicopathologic and molecular
features and are characterized by a high incidence of targetable mutations. Never smokers
with targetable mutations have significantly longer survival compared to patients without
mutations.
Introduction
Although the majority of lung cancer cases are associated with tobacco smoking, a consider-
able proportion (~10–40%) of patients develop lung cancer without a significant personal his-
tory of tobacco use [1–5]. Lung cancer in never smokers (LCINS) constitutes an entity with
distinct gender, geographic, clinicopathologic and molecular characteristics compared to lung
cancer occurring in smokers [2,3]. The majority (~65%-87% [1,6–8]) of never smoker patients
with lung cancer are women, and the incidence of LCINS is significantly higher in certain
geographic regions, including East Asia, than in the United States and in Europe [1,9,10].
Molecular profiling studies have shown that never smokers with lung adenocarcinoma harbor
significantly lower somatic mutation burden than smokers with the same disease [11]. Besides,
C> A transversions are more common in smokers, while C> T transitions occur more fre-
quently in never smokers [12]. EGFR mutations and ALK rearrangements appear to be more
frequent in never smokers than in smokers, whereas KRAS and BRAF mutations are less com-
mon in this subset of patients [6,13,14]. The majority of previous studies that have character-
ized the genomic alterations of LCINS have come from East Asia due to the high incidence of
LCINS in this geographic region. In contrast, data on the molecular characteristics of LCINS
in Western populations are scarce [1,6].
The aim of the current study was to analyze the molecular features of Swiss never smoker
patients with lung adenocarcinoma and to correlate the mutation status with demographic
and clinicopathologic characteristics and outcome. Because lung adenocarcinoma is the
most common histologic subtype in never smokers with non-small cell lung cancer (NSCLC)
accounting for up to 94% of LCINS [7], we focused on never smokers with adenocarcinoma
histology.
Methods
Patients and data collection
We performed a retrospective analysis of demographic, clinical and pathologic data stored in
the electronic medical record system at the University Hospital Zurich of all never smokers
with a pathologic diagnosis of stage I-IV lung adenocarcinoma, radio-chemotherapy and tar-
geted therapy naïve, diagnosed at our institution between January 2011 and January 2018.
Inclusion criteria were: 1) being a self-declared never smoker; 2) a diagnosis of histologically
and/or cytologically confirmed lung adenocarcinoma; 3) radio-chemotherapy and targeted
therapy naïve; and 4) tissue blocks/cell blocks with adequate tumor cellularity. Exclusion crite-
ria were: 1) non-adenocarcinoma histology; 2) previous chemotherapy, targeted therapy or
radiotherapy; and 3) insufficient tumor material. Never smokers were defined as individuals
who had smoked less than 100 cigarettes in their lifetime. The following data were retrieved
from the electronic patient record system: gender, ethnicity, age at diagnosis, clinical stage at
diagnosis, TNM stage at diagnosis (according to the Union for International Cancer Control
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(UICC) TNM classification of malignant tumors, 8th edition [15]), tumor location, tumor size,
type and duration of systemic treatment, and survival history. Overall survival was measured
from the date of pathologic diagnosis until the date of death. Patients were censored on May
31, 2018 if they were alive. Patients without a known date of death were censored at the time of
last follow-up. The diagnosis of lung adenocarcinoma was made on hematoxylin and eosin
stained and immunostained formalin-fixed, paraffin-embedded tissue sections from resection
or biopsy specimens and/or on cytologic samples based on the 2015 World Health Organiza-
tion classification for lung tumors [16]. The study was approved by the Cantonal Ethics Com-
mittee of Zurich (StV-No. 2018–01919), and written informed consent was obtained from all
patients, including written permission of two patients to publish their PET-CT scans.
Molecular analysis and immunohistochemistry
Tumor tissues from core biopsies (58.7%), resection specimens (30.4%) and cytologic samples
(10.9%) were used to perform all molecular analyses according to the National Comprehensive
Cancer Network (NCCN) and Swiss Society of Pathology (SSPath) guidelines, as previously
described [17]. Specific genotyping methods utilized included Sanger sequencing (SS) of
EGFR, KRAS, ERBB2 and BRAF, immunohistochemistry (IHC)/immunocytochemistry (ICC)
assays for ALK and ROS1, break-apart fluorescence in situ hybridization (FISH) for ALK,
ROS1 and RET and targeted DNA- and RNA-based next-generation sequencing (NGS). Tar-
geted DNA- and RNA-based NGS was performed in 69 patients using different customer
panels during the study period, including the Ion AmpliSeq Colon and Lung Cancer panel 2
(CLP2), Ion AmpliSeq Fusion Lung Cancer Research panel (LFP), and Oncomine DNA panel
for Solid Tumors and Fusion Transcripts (Thermo Fisher Scientific/Life Technologies, Carls-
bad, California, USA). We used the Ion Library Quantitation kit (Thermo Fisher Scientific) for
quantification of DNA and RNA libraries, the Ion One Touch 200 Template Kit v2 DL (lately
replaced by the Ion Hi-Q Chef Kit and the Ion Chef System) (Thermo Fisher Scientific) for
emulsion polymerase chain reaction (PCR) and template preparation, and the Ion Personal
Genome Machine 200 Kit v2 (lately replaced by the Ion Personal Genome Machine Hi-Q
Sequencing Kit) (Thermo Fisher Scientific) as sequencing platform. For Sanger sequencing,
we used the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare Life Sci-
ences, Buckinghamshire, UK) for purification of amplified DNA fragments, the Genetic Ana-
lyzer 3130x1 (Applied Biosystems, Foster City, CA, USA) for sequencing and the Sequencher
5.1 (Gene Code Corporation, Ann Arbor, MI, USA) for data analysis. ALK and ROS1 immu-
nohistochemistry (IHC)/immunocytochemistry (ICC) was performed on the automated
immunostainer DiscoveryUltra (Roche Ventana) using a mouse anti-human ALK monoclonal
antibody (clone 5A4, Leica Biosystems) and a rabbit anti-human ROS1 monoclonal antibody
(clone D4D6, Cell Signaling Technology). ALK or ROS1 IHC/ICC positive cases were con-
firmed by FISH using the Vysis LSI ALK Dual Color Break Apart Rearrangement Probe
(Abbott Molecular, Baar, Switzerland) and the ZytoLight SPEC ROS1 Dual Color Break Apart
Probe (Zytovision GmbH, Bremerhaven, Germany). FISH testing for RET rearrangement was
performed using the ZytoLight SPEC RET Dual Break Apart Probe (Zytovision GmbH, Bre-
merhaven, Germany).
Statistical analysis
Descriptive statistics were applied to describe the patient characteristics of the study cohort.
The results are presented as frequencies and percentages for categorical variables and as
mean ± standard deviation, median and range for continuous variables. Univariate analysis
was performed to assess associations between mutation status and clinicopathologic and
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demographic characteristics, using chi-square test or Fisher exact test for categorical variables
and t test or non-parametric Mann-Whitney test for continuous variables. Median overall sur-
vival (mOS) was estimated using the Kaplan-Meier method, and survival curves were com-
pared with the log-rank test. Adjusted hazard ratios were calculated using Cox regression
models (with a backward stepwise selection method) that included age, gender, clinical stage
and treatment as independent variables. P-values < 0.05 were considered statistically signifi-
cant. All statistical analyses were performed using SPSS Statistics software (version 24.0, IBM,
Ehningen, Germany).
Results
Patients
We identified 138 never smokers who fulfilled the inclusion criteria. Patient and tumor charac-
teristics are summarized in Table 1. Most patients were female (81/138, 58.7%), with a median
age at diagnosis of 64.5 years (mean, 63.3 ± 13.1 years; range, 27.1–94.2 years), and presented
with clinical stage IV (95/138, 68.8%). 15.2% (21/138) of patients had brain metastases at diag-
nosis, and 12.3% (17/138) of patients developed brain metastases during follow-up. Of the
entire study population, 8 (8/138, 5.8%) patients were lost to follow-up, and 130 (130/138,
94.2%) patients, including 116 patients with oncogenic driver mutations, were followed up
for a median time of 28.5 months (mo) (mean, 31.6 ± 19.0 mo, range, 2–84 mo). 56 (56/130,
43.1%) patients died during follow-up, while 74 (74/130, 56.9%) patients were alive at last fol-
low-up, including 45 (45/130, 34.6%) patients with stable disease and 29 (29/130, 22.3%)
patients with progressive disease. Median OS for the evaluable patients was 51.0 mo (mean,
52.0 ± 3.2 mo). 46 (46/130, 35.4%) patients received one treatment modality, while 84 (84/130,
64.6%) patients were treated with combined therapies. Treatment consisted of surgery in 54
(54/130, 41.5%) patients, chemotherapy in 88 (88/130, 67.7%) patients, radiotherapy in 40 (40/
130, 30.8%) patients and molecular targeted therapy in 61 (61/130, 46.9%) patients. Patients
with EGFR mutation and ALK rearrangement were treated with targeted therapy in 59.8% (55/
92). The majority of patients with stage IV disease for whom information about treatment was
available (86/89, 96.6%) received first-line systemic (targeted or chemotherapy) treatment.
Most of the chemotherapy-treated patients (including those who underwent chemo-radiother-
apy) received platinum-based regimens (94%). Among individuals for whom information
about treatment was available, 92.9% (26/28) of patients with stage I-IIIA, 89.7% (35/39) of
patients with stage I-IIIB and 87.8% (36/41) of patients with stage I-IIIC underwent surgical
resection.
Mutation analyses
At least one mutation was present in 125 (90.6%) of 138 analyzed tumors. EGFR (exon 19 dele-
tions– 45/81, 55.6%, exon 21 p.L858R point mutation– 26/81, 32.1%) was the most common
mutation (81/138, 58.7%, NGS: 33, SS: 48) (Table 2), followed by ALK (17/138, 12.3%, NGS: 3,
FISH: 14), TP53 (8/138, 5.8%, NGS: 8), MET (8/138, 5.8%, NGS: 8), KRAS (6/138, 4.3%, NGS:
3, SS: 3), ERBB2 (6/138, 4.3%, NGS: 3, SS: 3), PIK3CA (4/138, 2.9%, NGS: 4), BRAF (3/138,
2.2%, NGS: 2, SS: 1), ROS1 (2/138, 1.4%, NGS: 2), RET (2/138, 1.4%, NGS: 1, FISH: 1),
CTNNB1 (1/138, 0.7%, NGS: 1), PARP1 (1/138, 0.7%, NGS: 1), TET1 (1/138, 0.7%, NGS: 1)
and PIK3CG (1/138, 0.7%, NGS: 1) (Table 1). Doublet EGFR mutations were present in 9 (9/
138, 6.5%) tumors, including 4 tumors with p.L858R and non-p.L858R missense mutations
and 5 tumors with two non-p.L858R missense mutations (S1 Table). Of 21 tumors with multi-
ple mutations, 17 (17/21, 81.0%) had EGFR as a co-mutation (S1 Table). Mutations were not
detected in 13 (9.4%) of 138 tumors (pan-negative), and 34 (24.6%) of 138 tumors were triple-
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Table 1. Patient and tumor characteristics.
Clinical and demographic characteristics
All patients (n = 138) All patients (n = 138)
Age (years) Distribution
Median (range) 64.5 (27.1–94.2) Central 32 (23.2)
Mean 63.3 ± 13.1 Peripheral 83 (60.1)
Gender Central and peripheral 23 (16.7)
Male 57 (41.3) T stage
Female 81 (58.7) T1 19 (13.8)
Ethnicity T2 39 (28.3)
Caucasian 130 (94.2) T3 25 (18.1)
Asian 4 (2.9) T4 55 (39.9)
Other 4 (2.9) Lymph node involvement 105 (76.1)
Clinical stage at diagnosis N stage
I 9 (6.5) N0 33 (23.9)
II 11 (8.0) N1 16 (11.6)
III 23 (16.7) N2 39 (28.3)
IV 95 (68.8) N3 50 (36.2)
Localization Extrathoracic metastasis/-es 65 (47.1)
Right upper lobe 31 (22.5) M stage
Right lower lobe 14 (10.1) M0 43 (31.2)
Middle lobe 8 (5.8) M1a 30 (21.7)
Left upper lobe 27 (19.6) M1b 18 (13.0)
Left lower lobe 22 (15.9) M1c 47 (34.1)
Lingula 2 (1.4) Brain metastases at diagnosis 21 (15.2)
Involvement of two lobes 34 (24.6) Brain metastases at diagnosis
and during follow-up
38 (27.5)
Size (mm)
Mean 46.3 ± 24.5 Malignant pleural effusion 40 (29.0)
Molecular characteristics
All patients (n = 138) Patients tested†
EGFR 81/138 (58.7) EGFR 81/138 (58.7)
ALK 17/138 (12.3) ALK 17/108 (15.7)
MET 8/138 (5.8) MET 8/53 (15.1)‡
KRAS 6/138 (4.3) KRAS 6/114 (5.3)
ERBB2 6/138 (4.3) ERBB2 6/74 (8.1)
PIK3CA 4/138 (2.9) PIK3CA 4/58 (6.9)
BRAF 3/138 (2.2) BRAF 3/72 (4.2)
ROS1 2/138 (1.4) ROS1 2/78 (2.6)
RET 2/138 (1.4) RET 2/52 (3.8)
Other 10/138 (7.2) Other 10/56 (17.9)
Triple negative 34/138 (24.6) Triple negative 34/104 (32.7)
Pan-negative 13/138 (9.4) Pan-negative 13/56 (23.2)
Treatment
Patients with information about treatment (n = 130)
Surgery 54 (41.5)
Chemotherapy 88 (67.7)
Radiotherapy 40 (30.8)
Targeted therapy 61 (46.9)
(Continued)
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negative (EGFR negative/ALK negative/KRAS negative) (Table 1). KRAS mutations were most
frequently located in exon 2/codon 12 (5/6, 83.3%), and p.G12V (3/6, 50.0%) was the most
common subtype (Table 2). ERBB2 mutations were exclusively exon 20 insertions/duplica-
tions, and the most frequent ERBB2 mutation was p.A771_M774dup (2/6, 33.3%) (Table 2).
Of 21 patients with brain metastases at diagnosis, 15 (15/21, 71.4%) had EGFR mutation, 2 (2/
21, 9.5%) were pan-negative, 2 (2/21, 9.5%) had ALK translocation, 1 (1/21, 4.8%) harbored
PIK3CA mutation and 1 (1/21, 4.8%) harbored MET exon 14 skipping mutation.
Correlation with clinicopathologic characteristics
No statistically significant differences were found between male and female never smokers
with respect to clinical stage, TNM stage, presence of brain metastasis at diagnosis and dur-
ing follow-up, tumor location, mean tumor size, mean patient age at diagnosis and the fre-
quency of oncogenic driver mutations (S2 Table). Comparative analyses of EGFR mutated
tumors with EGFR wildtype, pan-negative and ALK positive tumors showed that EGFR
mutated tumors more frequently had extrathoracic metastases at diagnosis compared to
EGFR wildtype tumors (55.6% vs. 35.1%, p = 0.018) and were more commonly located in the
right upper lobe compared to EGFR wildtype, pan-negative and ALK positive tumors (28.4%
vs. 14.0%, p = 0.047; 28.4% vs. 0.0%, p = 0.033 and 28.4% vs. 0.0%, p = 0.010) (Table 3). There
was a significant difference in mean age between patients with EGFR mutated tumors and
those without identifiable mutations (61.9 ± 13.4 vs. 71.9 ± 9.2 years, p = 0.011) (Table 3)
as well as between patients with mutations in their tumors and the pan-negative cohort
(62.4 ± 13.2 vs. 71.9 ± 9.2 years, p = 0.012) (S3 Table). ALK rearranged lung adenocarcino-
mas were less frequently located in the right upper lobe (0.0% vs. 25.6%, p = 0.013) compared
to ALK wildtype tumors and more commonly showed ipsilateral mediastinal or subcarinal
lymph node metastasis (N2) compared to EGFR mutated and ALK wildtype tumors (52.9%
vs. 22.2%, p = 0.016 and 52.9% vs. 24.8%, p = 0.022) (Tables 3 and 4) (Fig 1). Comparative
analysis of patients with tumors harboring exon 21 p.L858R point mutation and patients
with tumors carrying exon 19 deletions showed significant differences in mean age, tumor
location (central vs. peripheral) and the frequency of ipsilateral mediastinal or subcarinal
lymph node metastasis (N2) and malignant pleural effusion (S4 Table). Patients with brain
metastases at diagnosis more frequently had T4 tumors and contralateral mediastinal, hilar
or supraclavicular lymph node metastasis (N3) compared to patients without brain metasta-
ses at diagnosis (61.9% vs. 35.9%, p = 0.025 and 61.9% vs. 31.6%, p = 0.008) (S5 Table). Like-
wise, patients with brain metastases at diagnosis and during follow-up more commonly
showed lymph node metastases compared to patients without brain metastases (92.1% vs.
70.0%, p = 0.007) (S6 Table). Lung adenocarcinoma diagnosed in patients < 45 years was
Table 1. (Continued)
EGFR 45/76 (59.2)
ALK 10/16 (62.5)
ERBB2 2/6 (33.3)
BRAF 1/3 (33.3)
MET 2/8 (25.0)
PIK3CA 1/1 (100)
Data are mean values ± standard deviations for continuous variables and number of patients with percentages in parentheses for categorical variables.
†Percentages in parentheses refer to the number of tested patients.
‡Exclusively patients tested for MET mutations (including MET exon 14 skipping mutations) with NGS.
https://doi.org/10.1371/journal.pone.0220691.t001
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Table 2. Oncogenic driver mutations in never smokers.
EGFR mutation (n = 81)
cDNA change Amino acid change Frequency Percentage
Exon 21 c.2573T>G p.L858R 26 32.1
Exon 21 c.2497T>G p.L833V 1 1.2
Exon 21 c.2560A>G p.T854A 1 1.2
Exon 21 c.2579A>T p.K860I 1 1.2
Exon 20 c.2303_2311dup p.S768_D770dup 2 2.5
Exon 20 c.2303G>T p.S768I 2 2.5
Exon 20 c.2320G>A p.V774M 1 1.2
Exon 20 c.2389T>A p.C797S 1 1.2
Exon 20 c.2320_2321insCACATG p.H773_V774insAH 1 1.2
Exon 20 c.2310_2311insGGGC p.D770_N771insG 1 1.2
Exon 20 c.2317_2322 p.H773_V774dup 1 1.2
Exon 19 c.2235_2249del/c.2236_2250del† p.E746_A750del 26 32.1
Exon 19 c.2240_2257del p.L747_P753delinsS 5 6.2
Exon 19 c.2237_2255delinsT p.E746_S752delinsV 3 3.7
Exon 19 c.2254_2277del p.S752_I759del 2 2.5
Exon 19 c.2240_2254del p.L747_T751del 2 2.5
Exon 19 c.2239_2256del p.L747_S752del 2 2.5
Exon 19 c.2239_2252delinsCA p.L747_T751delinsQ 1 1.2
Exon 19 c.2239_2248delinsC p.L747_A750delinsP 1 1.2
Exon 19 c.2239_2258delinsCA p.L747_P753delinsQ 1 1.2
Exon 19 c.2239_2251delinsC p.L747_T751delinsP 1 1.2
Exon 19 c.2251_2277del p.T751_I759delinsS 1 1.2
Exon 19 c.2281G>T p.D761Y 1 1.2
Exon 18 c.2156G>C p.G719A 2 2.5
Exon 18 c.2126A>C p.E709A 1 1.2
Exon 18 c.2126A>G p.E709G 1 1.2
Exon 18 c.2155G>T p.G719C 1 1.2
Exon 18 c.2142G>C p.K714N 1 1.2
KRAS mutations (n = 6)
cDNA change Amino acid change Frequency Percentage
Codon 12/Exon 2 c.35G>T p.G12V 3 50.0
Codon 12/Exon 2 c.34G>T p.G12C 1 16.7
Codon 12/Exon 2 c.35G>A p.G12D 1 16.7
Codon 61/Exon 3 c.182A>T p.Q61L 1 16.7
BRAF mutations (n = 3)
cDNA change Amino acid change Frequency Percentage
Exon 15 c.1799T>A p.V600E 2 66.7
Exon 15 c.1799T>A p.V600G 1 33.3
ERBB2 mutations (n = 6)
cDNA change Amino acid change Frequency Percentage
Exon 20 c.2324_2325ins p.E770_A771ins 1 16.7
Exon 20 c.2313_2324dup p.A771_M774dup 2 33.3
Exon 20 c.2326_2327insTGT p.G776delinsVC 1 16.7
Exon 20 c.2310_2311ins12 p.E770_A771insAYVM 1 16.7
Exon 20 c.2331_2339dup p.G778_P780dup 1 16.7
PIK3CA (n = 4)
(Continued)
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more commonly associated with lymph node metastasis (100.0% vs. 73.4%, p = 0.022), nota-
bly contralateral mediastinal, hilar or supraclavicular lymph node metastasis (N3) (64.3% vs.
33.1%, p = 0.021), and extrathoracic metastases (78.6% vs. 43.5%, p = 0.013) compared to
tumors diagnosed in patients > 45 years (S7 Table).
Correlation with outcome
Early clinical stage (in the entire study cohort–p = 0.002, Fig 2a; in all patients with mutations
in their tumors–p = 0.005, Fig 2b; in all patients with EGFR mutant and ALK rearranged
tumors–p = 0.005) and treatment with targeted therapy (in the entire study cohort–HR 2.53,
95% CI 1.35–4.74, p = 0.004, Fig 2c; in all patients with mutations in their tumors–HR 2.61,
95% CI 1.39–4.90, p = 0.003; and in the cohort with EGFR mutation or ALK rearrangement–
HR 2.22, 95% CI 0.99–4.99, p = 0.043) were independently associated with longer mOS.
Patients with mutations in their tumors had significantly longer mOS compared to patients
without mutations (mOS 52.2 vs. 16.9 mo; HR 3.38; 95% CI 1.52–7.55; p = 0.003, Fig 2d), and
patients with EGFR mutated tumors had significantly better outcome compared to patients
with EGFR wildtype and pan-negative tumors (mOS 57.8 vs. 35.0 mo, HR 2.35, 95% CI 1.37–
4.04, p = 0.002, Fig 2e, and mOS 57.8 vs. 16.9 mo, HR 7.80, 95% CI 3.28–18.55, p< 0.001).
Among the covariates included in the multivariable model (age, gender, clinical stage, treat-
ment) only treatment with targeted therapy and clinical stage were found significant. In the
subset of patients with EGFR mutant lung adenocarcinoma, no significant survival difference
was found between patients with tumors carrying exon 19 deletions and patients harboring
exon 21 p.L858R point mutation (mOS 47.0 vs. 58.7 mo, HR 1.02, 95% CI 0.34–3.08,
p = 0.977). In contrast, patients with ALK rearranged tumors had significantly longer OS com-
pared to the ALK wildtype and pan-negative cohorts (mOS 59.9 vs. 46.5 mo, HR 3.96, 95% CI
1.21–12.95, p = 0.023, Fig 2f and mOS 59.9 vs.16.9 mo, HR 34.78, 95% CI 3.48–34.65,
p = 0.003). Age, gender, clinical stage and treatment with targeted therapy proved to be signifi-
cant covariates in the multivariable regression model, and statistical significance for all vari-
ables was preserved when the analysis was restricted to the subset of patients for whom ALK
mutation status was known. Patients > 45 years had insignificantly longer OS compared to
patients < 45 years (mOS 50.7 vs. 36.2 mo, HR 1.04, 95% CI 0.49–2.23, p = 0.915, Fig 2g),
while patients with brain metastases at diagnosis had significantly shorter OS compared to
patients without brain metastases at diagnosis (mOS 24.6 vs. 51.5 mo, HR 2.62, 95% CI 1.24–
5.53, p = 0.012, Fig 2h).
Discussion
The study presents the molecular, demographic and clinicopathologic features of never
smoker patients with lung adenocarcinoma, diagnosed at a single institution in Switzerland.
We comprehensively analyzed associations between mutation status and clinicopathologic
characteristics and outcome.
Table 2. (Continued)
cDNA change Amino acid change Frequency Percentage
Exon 10 c.1633G>A p.E545K 2 50.0
Exon 10 c.1624G>A p.E542K 1 25.0
Exon 21 c.3140A>G p.H1047R 1 25.0
†c.2235_2249del: n = 18; c.2236_2250del: n = 8.
https://doi.org/10.1371/journal.pone.0220691.t002
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Table 3. Comparison of EGFR mutated tumors with EGFR wildtype, pan-negative and ALK positive tumors.
Variable EGFR mt
(n = 81)
EGFR wt
(n = 57)
p Pan-negative
(n = 13)
p ALK positive
(n = 17)
p
Age (years) 61.9 ± 13.4 65.3 ± 12.6 0.133 71.9 ± 9.2 0.011 64.2 ± 14.0 0.515
Gender 0.225 0.250 0.097
Male 30 (37.0) 27 (47.4) 7 (53.8) 10 (58.8)
Female 51 (63.0) 30 (52.6) 6 (46.2) 7 (41.2)
Clinical stage
I 6 (7.4) 3 (5.3) 0.736 1 (7.7) 0.971 0 (0.0) 0.586
II 5 (6.2) 6 (10.5) 0.361 1 (7.7) 0.839 2 (11.8) 0.601
III 10 (12.3) 13 (22.8) 0.104 3 (23.1) 0.381 5 (29.4) 0.130
IV 60 (74.1) 35 (61.4) 0.114 8 (61.5) 0.339 10 (58.8) 0.242
T stage
T1 11 (13.6) 8 (14.0) 0.939 0 (0.0) 0.352 3 (17.6) 0.705
T2 25 (30.9) 14 (24.6) 0.418 4 (30.8) 0.995 4 (23.5) 0.547
T3 18 (22.2) 7 (12.3) 0.135 1 (7.7) 0.455 2 (11.8) 0.670
T4 27 (33.3) 28 (49.1) 0.062 8 (61.5) 0.066 2 (11.8) 0.537
LN meta 59 (72.8) 46 (80.7) 0.286 10 (76.9) 0.754 15 (88.2) 0.228
N stage
N0 22 (27.2) 11 (19.3) 0.286 3 (23.1) 0.754 2 (11.8) 0.228
N1 10 (12.3) 6 (10.5) 0.742 2 (15.4) 0.670 1 (5.9) 0.683
N2 18 (22.2) 21 (36.8) 0.060 3 (23.1) 0.945 9 (52.9) 0.016
N3 31 (38.3) 19 (33.3) 0.552 5 (38.5) 0.990 5 (29.4) 0.491
Extrathoracic meta 45 (55.6) 20 (35.1) 0.018 5 (38.5) 0.252 5 (29.4) 0.050
M stage
M0 21 (25.9) 22 (38.6) 0.114 5 (38.5) 0.339 7 (41.2) 0.242
M1a 15 (18.5) 15 (26.3) 0.274 5 (38.5) 0.709 5 (29.4) 0.330
M1b 12 (14.8) 6 (10.5) 0.461 1 (7.7) 0.686 0 (0.0) 0.119
M1c 33 (40.7) 14 (24.6) 0.048 4 (30.8) 0.495 5 (29.4) 0.383
Localization
Right upper lobe 23 (28.4) 8 (14.0) 0.047 0 (0.0) 0.033 0 (0.0) 0.010
Right lower lobe 6 (7.4) 8 (14.0) 0.204 3 (23.1) 0.107 2 (11.8) 0.624
Middle lobe 5 (6.2) 3 (5.3) 0.821 1 (7.7) 0.839 2 (11.8) 0.601
Left upper lobe 15 (18.5) 12 (21.1) 0.712 3 (23.1) 0.709 4 (23.5) 0.736
Left lower lobe 12 (14.8) 10 (17.5) 0.666 2 (15.4) 0.957 3 (17.6) 0.721
Lingula 0 (0.0) 2 (3.5) 0.169 0 (0.0) - 1 (5.9) 0.173
Mixed 20 (24.7) 14 (24.6) 0.986 4 (30.8) 0.733 5 (29.4) 0.761
Distribution
Central 18 (22,2) 14 (24.6) 0.749 3 (23.1) 0.945 6 (35.3) 0.351
Peripheral 50 (61.7) 33 (57.9) 0.651 6 (46.2) 0.288 7 (41.2) 0.118
Central and peripheral 13 (16.0) 10 (17.5) 0.817 4 (30.8) 0.243 4 (23.5) 0.487
Malignant PE 28 (34.6 12 (21.1) 0.085 4 (30.8) 0.787 4 (23.5) 0.378
Size (mm) 45.7 ± 21.9 47.1 ± 28.0 0.755 55.0 ± 28.9 0.180 50.4 ± 36.9 0.486
Brain meta at diagnosis 15 (18.5) 6 (10.5) 0.198 2 (15.4) 0.782 2 (11.8) 0.729
Brain meta at diagnosis
and during follow-up
23 (28.4) 15 (26.3) 0.788 4 (30.8) 0.861 6 (35.3) 0.571
Data are mean values ± standard deviations for continuous variables and number of patients with percentages in parentheses for categorical variables.
Bold numbers indicate significant p-values (< 0.05).
https://doi.org/10.1371/journal.pone.0220691.t003
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Table 4. Comparison of ALK positive tumors with ALK negative and pan-negative tumors.
Variable ALK positive
(n = 17)
ALK negative†
(n = 121)
p ALK negative‡
(n = 91)
p Pan-negative
(n = 13)
p
Age (years) 64.2 ± 14.0 63.1 ± 13.1 0.753 63.9 ± 12.5 0.929 71.9 ± 9.2 0.098
Gender 0.117 0.166 7 (53.8) 0.785
Male 10 (58.8) 47 (38.8) 37 (40.7) 6 (46.2)
Female 7 (41.2) 74 (61.2) 54 (59.3)
Clinical stage
I 0 (0.0) 9 (7.4) 0.601 7 (7.7) 0.594 1 (7.7) 0.433
II 2 (11.8) 9 (7.4) 0.626 7 (7.7) 0.631 1 (7.7) 0.709
III 5 (29.4) 18 (14.9) 0.162 16 (17.6) 0.316 3 (23.1) 0.696
IV 10 (58.8) 85 (70.2) 0.341 61 (67.0) 0.513 8 (61.5) 0.880
T stage
T1 3 (17.6) 16 (13.2) 0.705 13 (14.3) 0.715 0 (0.0) 0.238
T2 4 (23.5) 35 (28.9) 0.779 23 (25.3) 0.878 4 (30.8) 0.698
T3 2 (11.8) 22 (18.2) 0.957 15 (16.5) 0.907 1 (7.7) 0.613
T4 2 (11.8) 48 (39.7) 0.905 40 (44.0) 0.832 8 (61.5) 0.269
LN meta 15 (88.2) 90 (74.4) 0.361 65 (71.4) 0.228 10 (76.9) 0.628
N stage
N0 2 (11.8) 31 (25.6) 0.361 26 (28.6) 0.228 3 (23.1) 0.628
N1 1 (5.9) 15 (12.4) 0.693 8 (8.8) 0.678 2 (15.4) 0.565
N2 9 (52.9) 30 (24.8) 0.022 25 (27.5) 0.038 3 (23.1) 0.098
N3 5 (29.4) 45 (37.2) 0.532 32 (35.2) 0.646 5 (38.5) 0.705
Extrathoracic meta 5 (29.4) 60 (49.6) 0.119 39 (42.9) 0.300 5 (38.5) 0.705
M stage
M0 7 (41.2) 36 (29.8) 0.341 30 (33.0) 0.513 5 (38.5) 0.880
M1a 5 (29.4) 25 (20.7) 0.529 22 (24.2) 0.761 3 (23.1) 0.696
M1b 0 (0.0) 18 (14.9) 0.127 14 (15.4) 0.120 1 (7.7) 0.433
M1c 5 (29.4) 42 (34.7) 0.666 25 (27.5) 0.870 4 (30.8) 0.936
Localization
Right upper lobe 0 (0.0) 31 (25.6) 0.013 24 (26.4) 0.012 0 (0.0) -
Right lower lobe 2 (11.8) 12 (9.9) 0.683 11 (12.1) 0.970 3 (23.1) 0.628
Middle lobe 2 (11.8) 6 (5.0) 0.256 3 (3.3) 0.175 1 (7.7) 0.709
Left upper lobe 4 (23.5) 23 (19.0) 0.744 17 (18.7) 0.739 3 (23.1) 0.977
Left lower lobe 3 (17.6) 19 (15.7) 0.735 10 (11.0) 0.427 2 (15.4) 0.869
Lingula 1 (5.9) 1 (0.8) 0.232 1 (1.1) 0.291 0 (0.0) 0.281
Mixed 5 (29.4) 29 (24.0) 0.764 25 (27.5) 0.870 4 (30.8) 0.936
Distribution
Central 6 (35.3) 26 (21.5) 0.225 19 (20.9) 0.217 3 (23.1) 0.691
Peripheral 7 (41.2) 76 (62.8) 0.088 59 (64.8) 0.066 6 (46.2) 0.785
Central and peripheral 4 (23.5) 19 (15.7) 0.485 13 (14.3) 0.466 4 (30.8) 0.698
Malignant PE 4 (23.5) 36 (29.8) 0.778 21 (23.1) 0.968 4 (30.8) 0.698
Size (mm) 50.4 ± 36.9 45.7 ± 22.4 0.461 46.4 ± 22.3 0.543 55.0 ± 28.9 0.714
Brain meta at diagnosis 2 (11.8) 19 (15.7) 0.663 11 (12.1) 0.970 2 (15.4) 0.773
Brain meta at diagnosis
and during follow-up
6 (35.3) 32 (26.4) 0.562 21 (23.1) 0.360 4 (30.8) 0.794
Data are mean values ± standard deviations for continuous variables and number of patients with percentages in parentheses for categorical variables.
†Patients with EGFR or KRAS mutation and unknown ALK mutation status included.
‡Analysis restricted to patients with known ALK mutation status. Bold numbers indicate significant p-values (< 0.05).
https://doi.org/10.1371/journal.pone.0220691.t004
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To the best of our knowledge, only two previous studies have thoroughly investigated the
genomic characteristics of LCINS in Western populations [1,6]. In the first study, a large
multicenter series from France, comprising 384 never smokers with NSCLC (adenocarci-
noma histology– 85%), Couraud et al. [6] reported ALK rearrangement and EGFR, KRAS,
BRAF, ERBB2 and PIK3CA mutation in 13%, 43%, 7%, 5%, 4% and 2% of tested patients,
respectively, using different genotyping methods in overall 75 participating centers. The
authors did not comprehensively analyze associations between mutation status and clinico-
pathologic and demographic patient characteristics, instead the study focused on epidemio-
logic data including information on exposure to occupational carcinogens and passive
Fig 1. ALK rearranged vs. ALK wildtype lung adenocarcinoma in never smokers. (A,B) PET-CT scans showing a
large tumor mass in the right lower lobe together with ipsilateral mediastinal lymph node metastasis. (C)
Adenocarcinoma morphology on cytological sample (May-Gru¨nwald stain, x 400). (D) Positive ALK fluorescence in
situ hybridization (FISH) with split signals and mainly isolated red signals. (E) PET-CT scan and (F) axial CT image
showing a tumor nodule in the right upper lobe without mediastinal lymph node metastases. (G) Adenocarcinoma
histology on resection specimen (hematoxylin & eosin stain, x 200). (H) ALK FISH negativity with fusion signals.
https://doi.org/10.1371/journal.pone.0220691.g001
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smoker exposure [6]. In the second study, a large retrospective single center series from Can-
ada, comprising 712 never smoking lung cancer patients (adenocarcinoma histology– 87%),
515 of whom had tumor tissue available for molecular analysis, Korpanty et al. [1] reported
EGFR, KRAS, TP53, ERBB2, BRAF and PIK3CA mutation and ALK rearrangement in 52.2%,
Fig 2. Overall survival in never smokers with lung adenocarcinoma. (A) Entire cohort by clinical stage at diagnosis.
(B) All patients with mutations by clinical stage at diagnosis. (C) Entire cohort by treatment with targeted therapy. (D)
All patients by presence of oncogenic driver mutations. (E) All patients by EGFR mutation status. (F) All patients by
ALK rearrangement status. (G) Entire cohort by age at diagnosis. (H) All patients by presence of brain metastases at
diagnosis. KM, Kaplan Meier; CR, Cox regression.
https://doi.org/10.1371/journal.pone.0220691.g002
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2.3%, 1.4%, 1,0%, 0.4%, 0.4% and 7.6% of patients, respectively, using MassARRAY technol-
ogy (Sequenom, San Diego, CA) or MiSeq (Illumina, San Diego, CA) NGS personal geno-
mics platforms as testing methods. In accordance with the above-mentioned studies [1,6]
and the results of investigations from Asian populations [7,18,19] EGFR mutation was the
most commonly encountered mutation type in our study population (58.7%), and the major-
ity (55.6%) of EGFR mutations were deletions in exon 19. It is well known that the reported
EGFR mutation rates in patients with lung adenocarcinoma vary widely among different
populations worldwide (ranging from 10–20% in European and North American cohorts
[20–23] to more than 50% in Asian populations [24,25]), and that EGFR mutation status is
significantly associated with female gender and never smoking status [20–25]. When we con-
fined the analysis to female never smokers in our cohort, we achieved a high EGFR mutation
rate of 63.0%, which is consistent with previous reports showing EGFR mutation rates reach-
ing up to 60% when focusing on female never smoker patients [24–26]. ALK translocations,
detected in 3–7% of non-selected NSCLC cohorts [27–29], are reported to occur more com-
monly in non-smokers, lung adenocarcinomas and non-Asian vs. Asian populations [30].
The frequency of ALK rearrangements in our study (12.3%) was similar to that reported for
never smoker subgroups in previous investigations (range, 4.5%-16.4% [7,18,28,29,31]). In a
recent study, we analyzed mutation frequencies and associations between mutational status
and clinicopathologic patient characteristics in a non-selected representative cohort of Swiss
patients with newly diagnosed lung adenocarcinoma the majority of whom (354/469, 75.5%)
were ever smokers (current smokers or ex-smokers) [17]. Compared with the current study,
we found a significantly higher percentage of KRAS mutation (159/469, 33.9%), which was
the most common mutation in this non-selected patient cohort, and lower frequencies of
EGFR mutation (90/469, 19.2%) and ALK rearrangement (28/469, 6.0%). Similar to the
results of the current study, EGFR mutated tumors more frequently had (multiple) extrathor-
acic metastases at diagnosis and tended to occur more frequently in the right upper lobe
compared to EGFR wildtype and ALK rearranged tumors, while ALK positive lung adenocar-
cinomas were less frequently located in the right upper lobe compared to ALK wildtype
tumors. In both studies, we found that ALK-rearranged tumors were more commonly associ-
ated with ipsilateral mediastinal or subcarinal lymph node metastasis (N2) compared to ALK
wildtype and EGFR mutated lung adenocarcinoma. In a non-selected stage I-III NSCLC pop-
ulation, Paik et al. [32] reported lower tumor stage (pT1) and significantly higher frequency
of lymph node metastases in ALK FISH-positive NSCLC cases compared to ALK FISH-nega-
tive NSCLC cases. The authors suggested that ALK-rearranged lung cancer might have
unique biological features with a tendency to early lymph node metastasis despite small pri-
mary tumor size, which could explain higher incidences of ALK rearrangement in advanced
NSCLC when compared with surgically resectable lung cancer [32].
Recent studies have suggested that never smoker patients with tumors harboring mutations
may have significantly longer mOS compared to patients without identifiable mutations [1].
Besides, never smokers with ALK rearranged NSCLC are reported to have significantly better
outcome compared to the ALK wildtype and pan-negative cohorts [1,7]. In accordance with
these reports, patients with oncogenic driver mutations in our study had significantly longer
mOS compared to patients without identifiable mutations, and patients with ALK transloca-
tion had significantly better outcome compared to patients without ALK rearrangement and
the pan-negative cohort. Similarly, the presence of EGFR mutation in our study was signifi-
cantly associated with longer OS in univariable and multivariable analysis, while, consistent
with the results reported by Korpanty et al. [1] and in contrast to previous reports [33,34], no
significant survival difference was found between patients with tumors harboring EGFR exon
19 deletions and patients with tumors harboring EGFR exon 21 mutations.
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The initial onset of brain metastases is generally considered an unfavorable prognostic fac-
tor that increases the risk of death [35]. In a recent study, Korpanty et al. [1] found no signifi-
cant survival difference in patients with and those without brain metastases at diagnosis. The
authors suggested that the lack of survival difference may be related to the high proportion
(~80%) of tumors harboring EGFR mutation or ALK translocation among patients with brain
metastases in their study [1], as these mutations are known to be associated with favorable
response of CNS disease to targeted tyrosine kinase inhibitors and higher response rates to
whole brain radiation therapy compared to wildtype lung cancer [36–40]. In our study,
patients with brain metastases at diagnosis had significantly shorter mOS compared to patients
without brain metastases at diagnosis despite the fact that 81.0% of patients with brain metas-
tases at presentation had tumors with two most common targetable mutations (71.4%–EGFR,
9.5%–ALK).
NSCLC diagnosed in young patients is a rare entity, with incidences ranging between 1.3
and 5.3% among patients� 45 years at diagnosis [4,41–43]. The genomics and clinical charac-
teristics of this disease are poorly understood, and studying the relationship between age and
genotype in young NSCLC patients is challenging due to multiple confounding factors such as
gender, race and smoking status [44]. Previous reports have indicated that younger age may be
associated with an increased likelihood of harboring oncogenic driver mutations in patients
with NSCLC [44,45]. Besides, recent data suggest that ALK rearrangements occur more fre-
quently in younger NSCLC patients compared to older patients with lung cancer [44–47],
whereas KRAS mutations appear to be less frequent in the younger patient cohort [44,45].
Regarding EGFR mutation frequency, a study by Sacher et al. [44] comprising 2237 NSCLC
patients found an increased likelihood of EGFR mutations in patients diagnosed with NSCLC
at a younger age, while Tanaka et al. [45] reported a significantly lower frequency of EGFR
mutations in 81 lung adenocarcinoma patients� 40 years compared with 1665 lung adenocar-
cinoma patients > 40 years at initial diagnosis. In our study, focusing on never smoker
patients with adenocarcinoma histology, we found no significant differences in the frequency
of EGFR mutation, KRAS mutation or ALK translocation between patients < 45 years and
patients� 45 years. 92.9% of patients< 45 years in our study had potentially targetable genetic
alterations in EGFR, ALK, ROS1 and MET, 78.6% had EGFR mutation or ALK rearrangement
(71.4%–EGFR, 7.1%–ALK), and 14.3% had tumors harboring TP53 mutation. Consistent with
previous results [44,45], patients < 45 years had shorter mOS compared to patients� 45
years, although the difference in survival was not statistically significant in our cohort. It has
been suggested that the worse prognosis in young NSCLC patients could be partly related to
the significantly higher prevalence of TP53 mutations in young patients with lung adenocarci-
noma [45,48]. However, further studies are needed to investigate the underlying mechanisms
that explain the more aggressive biology of lung cancer in younger patients.
There are several limitations to this study. First, this is a retrospective analysis of highly
selected patients diagnosed and treated from 2011–2018 at a single tertiary referral academic
institution. During that time, different sequencing methods were used, and we are aware of
the heterogeneity of molecular testing methods and the fact that molecular pathology data
were not completely comprehensive for all patients, which might have influenced the results of
the current study. In addition, due to rapidly changing treatment guidelines different treat-
ment regimens and sequence of these therapies were applied during the study period, includ-
ing the incorporation of targeted therapy in routine practice for selected patients, and we
acknowledge that our analyses are limited by the heterogeneity of treatment modalities and
different combinations of therapies. Second, we did not attempt to identify comorbidities or
specific exposures that may contribute to lung cancer risk including exposure to other carcino-
gens such as asbestos, radon, radiation therapy, and various other exposures in environmental,
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medical and/or occupational settings. Given the retrospective nature of the study, our analyses
are further limited by uncertainties about errors and incompleteness of information about
smoking exposure. Last, we did not analyze associations between programmed death-ligand 1
(PD-L1) expression and molecular features or outcome, although recent studies have shown
that the predictive value of PD-L1 in NSCLC patients may be influenced by oncogenic driver
mutation status [49]. Future prospective studies are needed to comprehensively investigate
PD-L1 expression and the efficacy of PD-1/PD-L1 inhibitor therapy in different subsets of
never smoker patients with oncogenic driver mutations.
Conclusion
This is the first comprehensive analysis of molecular, clinicopathologic and survival data of
never smokers with lung adenocarcinoma diagnosed at a tertiary referral academic hospital in
Switzerland. There was a high incidence of oncogenic driver mutations in our study popula-
tion, and EGFR mutation and ALK rearrangement were the most common genetic alterations.
EGFR mutated tumors were more commonly associated with extrathoracic metastases at diag-
nosis compared to EGFR wildtype tumors, while ALK rearranged tumors more commonly
had ipsilateral mediastinal or subcarinal lymph node metastasis compared to EGFR mutated
and ALK wildtype tumors. Patients < 45 years more commonly showed lymph node metasta-
sis and extrathoracic metastases compared to patients > 45 years. Consistent with previous
Table 5. Most relevant study results.
Most common mutations:
EGFR (81/138,58.7%), ALK (17/138, 12.3%), TP 53 (8/138, 5.8%), MET (8/138, 5.8%), KRAS (6/138, 4.3%), ERBB2
(6/138, 4.3%), PIK3CA (4/138, 2.9%), BRAF (3/138, 2.2%), ROS1 (2/138, 1.4%), RET (2/138, 1.4%)
Correlation with clinicopathologic characteristics:
EGFR mutated vs. EGFR wildtype tumors
- extrathoracic metastases at diagnosis (55.6% vs. 35.1%, p = 0.018)
ALK rearranged vs. ALK wildtype tumors
- ipsilateral mediastinal or subcarinal lymph node metastasis (52.9% vs. 24.8%, p = 0.022)
ALK rearranged vs. EGFR mutated tumors
- ipsilateral mediastinal or subcarinal lymph node metastasis (52.9% vs. 22.2%, p = 0.016)
Patients < 45 years vs. patients > 45 years
- lymph node metastasis (100.0% vs. 73.4%, p = 0.022)
- extrathoracic metastases (78.6% vs. 43.5%, p = 0.013)
Correlation with outcome:
Patients with mutations vs. patients without mutations
- mOS 52.2 vs. 16.9 mo, p = 0.003
Patients with EGFR mutated vs. EGFR wildtype tumors
- mOS 57.8 vs. 35.0 mo, p = 0.002
Patients with EGFR mutated vs. pan-negative tumors
- mOS 57.8 vs. 16.9 mo, p< 0.001
Patients with ALK rearranged vs. ALK wildtype tumors
- mOS 59.9 vs. 46.5 mo, p = 0.023
Patients with ALK rearranged vs. pan-negative tumors
- mOS 59.9 vs. 16.9 mo, p = 0.003
Patients with brain metastasis at diagnosis vs. patients without brain metastasis at diagnosis
- mOS 24.6 vs. 51.5 mo, p = 0.012
mOS: median overall survival.
https://doi.org/10.1371/journal.pone.0220691.t005
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reports never smokers with oncogenic driver mutations had significantly longer OS compared
to patients without identifiable mutations. Likewise, there were significant differences in sur-
vival between patients with EGFR mutated vs. EGFR wildtype tumors, EGFR mutated vs. pan-
negative tumors, ALK rearranged vs. ALK wildtype tumors and ALK rearranged vs. pan-nega-
tive tumors (Table 5).
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